Kamada’s philosophy embraces the joining of forces with industry partners. As each partner brings unique strengths and abilities into the partnership, a greater whole is created.

As a fully-integrated pharmaceutical company, Kamada is looking to complement the partners’ knowledge, skills and resources with its own proprietary technology, production and marketing capabilities and extensive experience in the pharmaceutical industry.
As for now, Kamada’s strategic alliances include agreements with several partners, with a focus on product development, technology and distribution rights, as well as on the supply of raw materials.

Some of Kamada's Partnerships:

  • Strategic exclusive agreement with Baxter Healthcare Corporation for manufacturing, marketing and distributing of Glassia®, Kamada's Alpha-1 antitrypsin product, in the US, Canada, Australia and New Zealand markets.
  • Strategic agreement with Chiesi for future marketing & distributing of Aerosolized AAT in Europe.
  • Kamada´s product line consists of more than 10 products which are marketed through local distributors, in more than 15 countries worldwide.
  • Development of an inhaled AAT treatment (currently at clinical phase III) through collaboration with PARI, a worldwide leader in inhalation devices (www.paripharma.com)
  • Strategic agreement with a leading biopharma company (Kedrion S.p.A) for clinical development and marketing of KamRAB, Kamada's Rabies IgG product, in the US.
  • Collaboration with Israel Ministry of Health to develop a technology platform for manufacturing anti-snake serum to treat snake bites.
  • Exclusive marketing and distribution in Israel of leading international pharmaceutical companies, which complements Kamada's line of products and fields of activity: BPL, Biotest, Rotex Aguattant, Chiesi

Partnering Possibilities

Among possible collaborations, the following are particularly exciting for us, involving Kamada’s most innovative products and unique capabilities:

  • Global partnerships/distributorships in various territories to bring Kamada’s unique products to new markets
  • Strategic partnerships concerning Kamada's clinical pipeline
  • Strategic collaborations to develop new indications and applications for Transferrin: As Kamada is a world-leading Transferrin manufacturer and IP holder, developers of anti-cancer, Transferrin-conjugated drugs can find in us a natural strategic partner and supplier. In particular, the company has established experience in the production of Human Transferrin for diagnostic/in vitro uses.

Business Development contact details: